Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
PVLA submitted a Form 144 notice for the proposed sale of common shares scheduled 02/18/2026, identified as an option exercise to be settled for cash. The filing lists prior sales by Kathleen Goin, including 419,983 shares on 01/21/2026 and 415,022 shares on 12/17/2025.
Palvella Therapeutics, Inc. received a Schedule 13G reporting that First Light Asset Management, LLC and its managing member Mathew P. Arens beneficially own 887,031 shares of Palvella common stock, representing 7.49% of the outstanding class as of 12/31/2025.
The shares are held in separately managed accounts and private funds advised by First Light, with both First Light and Arens sharing voting and dispositive power over all 887,031 shares and no sole voting or dispositive power. The filing certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Palvella.
Palvella Therapeutics, Inc. received an amended Schedule 13G/A (Amendment No. 3) reporting that funds and entities associated with Biotechnology Value Fund and Mark N. Lampert beneficially owned 879,009 shares of Palvella common stock as of December 31, 2025.
These shares represent approximately 7.1% of Palvella’s outstanding common stock, based on 11,836,490 shares outstanding as of November 7, 2025 plus 535,839 shares issued to the reporting persons and a managed account upon exercise of certain pre-funded warrants.
Ownership is spread across BVF, BVF2, Biotechnology Value Trading Fund OS and related general partners and managers, all of which report shared voting and dispositive power. The group certifies the position is not held for the purpose of changing or influencing control of Palvella.
Palvella Therapeutics, Inc. received an amended Schedule 13G/A from several Frazier Life Sciences entities reporting passive ownership of its common stock. Frazier Life Sciences Public Fund, L.P. directly holds 706,360 shares, representing 6.0% of the common stock, based on 11,836,490 shares outstanding as of November 7, 2025. Other affiliated Frazier funds hold smaller positions of 4,730, 7,517 and 3,793 shares. The group also holds prefunded warrants for additional shares that are subject to a 4.99% beneficial ownership cap upon exercise. The reporting persons certify the securities were not acquired to change or influence control of Palvella.
Palvella Therapeutics, Inc. disclosed that its Chief Scientific Officer, Jeffrey S. Martini, received a stock option grant. On February 5, 2026, he was awarded options to purchase 64,318 shares of common stock at an exercise price of $76.43 per share, granted for no cash cost.
The option vests in equal monthly installments over 48 months, beginning February 5, 2026, and each vesting installment requires his continuous service through the applicable vesting date.
Palvella Therapeutics, Inc. granted its Chief Commercial Officer, Ashley Hartmann, a stock option for 38,517 shares of common stock on February 5, 2026. The option has an exercise price of $76.43 per share and expires on February 5, 2036.
The option vests in equal monthly installments over 48 months, starting February 5, 2026, and remains subject to Hartmann’s continuous service with the company through each vesting date. All 38,517 derivative securities are reported as directly owned following this grant.
Palvella Therapeutics President and CEO Wes Kaupinen received a grant of 124,603 stock options on February 5, 2026. The options have an exercise price of $76.43 per share and are held directly.
The award vests in equal monthly installments over 48 months starting February 5, 2026, contingent on his continued service. Following this grant, Kaupinen beneficially owns 124,603 derivative securities tied to Palvella Therapeutics common stock.
Palvella Therapeutics, Inc. reported that CFO and Treasurer Matthew E. Korenberg received a grant of stock options for 44,123 shares of common stock on February 5, 2026. The options carry an exercise price of $76.43 per share and expire on February 5, 2036.
The options vest in equal monthly installments over 48 months starting February 5, 2026, as long as he remains in continuous service through each vesting date. Following this award, he beneficially holds 44,123 derivative securities directly.
Palvella Therapeutics Chief Operating Officer Kathleen Goin reported receiving a stock option grant. On February 5, 2026, she was awarded options to purchase 48,956 shares of common stock at an exercise price of $76.43 per share, expiring February 5, 2036.
The options vest in equal monthly installments over 48 months starting February 5, 2026, and each vesting date requires her continued service. All 48,956 derivative securities are held directly following this grant.